亞旭生物科技

GLP-1R, GIPR, and GCGR are key targets for diabetes and obesity treatment. GLP-1R enhances insulin secretion and satiety, while GIPR and GCGR regulate glucose and energy balance. Therapeutics like GLP-1R agonists (e.g., semaglutide), dual agonists (e.g., tirzepatide), and triple agonists (e.g., retatrutide) have shown promise in treating metabolic disorders. Sino Biological’s recombinant GLP-1R, GIPR, and GCGR proteins provide essential tools in this area of research.

READ MORE

Featured Products from Sino Biological


Validated activity	Broad coverage of tags	Highly cited in reputable journals

	Human GCGR recombinant-proteins
	HPLC-verified (Cat#: 30122-H08H)
	ELISA. Binding of human anti-GCGR (Volagidemab) to recombinant human GCGR protein.

	Human GLP-1R Protein
	Nanodisc (Cat#: 13944-H88H-NA)
	ELISA. Binding of Human GLP1R-Nanodisc Protein to Anti-GLP1R mAb.

View More GLP-1R, GCGR, and GIPR Proteins

View Poster

This poster features the physiologic roles of GLP-1R, GIPR, and GCGR, as well as their potential as therapeutic targets for diabetes and obesity. In addition, research applications and drug development targeting these targets are discussed.

View Poster Now

	Sino Biological US Inc. (U.S.A.)
	order_us@sinobiologicalus.com
	Sino Biological Europe GmbH (Europe)
	order_eu@sinobiologicaleu.com

	Sino Biological, Inc. (China)
	order@sinobiological.com
	株式会社日本シノバイオロジカル (Japan)
	order@sinobiological.co.jp

SinoBiological | 肥胖 (Obesity) 與糖尿病 (Diabetes) 的關鍵標的：GLP-1R, GIPR, 和 GCGR

SinoBiological | 肥胖 (Obesity) 與糖尿病 (Diabetes) 的關鍵標的：GLP-1R, GIPR, 和 GCGR

LINE 線上諮詢